StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
ALDXAldeyra Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$0.6205▼ 4.98%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $37.4MShares out 60.3M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

5
  • 9.29Pre-market26.09.29 20:01
    8-KKey event#●●●#●●●

    Aldeyra Therapeutics, Inc.

    Aldeyra Therapeutics has announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs, appealing the previous denial of its New Drug Application for reproxalap in treating dry eye disease. Additionally, the company reported $45.1 million in cash and cash equivalents as of June 30, 2026, extending its operational cash runway into 2029.…more

    $0.6205-4.98%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.12Regular26.08.12 23:48
    SCHEDULE 13GOwnership

    Aldeyra Therapeutics, Inc.

    AQR Capital Management LLC has filed a Schedule 13G regarding its stake in Aldeyra Therapeutics, Inc. This filing serves as a formal notification of beneficial ownership, confirming that the institutional investor holds more than 5% of the company's shares.…more

    $0.6205-4.98%vs prev close
    View filingShare
  • 8.6After-hours26.08.07 05:02
    10-QEarnings

    Aldeyra Therapeutics, Inc.

    알데이라 테라퓨틱스(ALDX)는 2026년 2분기 실적 보고를 통해 순손실 545만 달러(주당 0.09달러)를 기록했으며, 상반기 누적 순손실은 890만 달러로 집계되었습니다. 2026년 6월 30일 기준 현금 및 현금성 자산은 4,509만 달러이며, 총 발행 주식 수는 6,032만 1,068주입니다.…more

    $0.6205-4.98%vs prev close
    View filingShare

4 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.29Regular26.09.30 03:34
    #●●●#●●●

    Aldeyra Therapeutics to File Formal Dispute Over FDA Rejection

    Aldeyra Therapeutics shares rose as the company announced plans to submit a formal dispute resolution request regarding the FDA's rejection of its dry eye drug. This move initiates a regulatory challenge, though the ultimate approval remains uncertain.…more

    $0.6205-4.98%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga